DCM
VRNA

DAFNA Capital Management’s Verona Pharma VRNA Stock Holding History

DAFNA Capital Management’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-18,337
Closed -$153K – 93
2021
Q1 		$153K Sell
18,337
-143,170
-89% -$1.19M 0.04% 88
2020
Q4 		$1.13M Hold
161,507
– – 0.34% 56
2020
Q3 		$1.01M Buy
+161,507
New +$1.12M 0.33% 56

Other funds holding VRNA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

DAFNA Capital Management's VRNA Position: Q2 2021 in Review

DAFNA Capital Management sold out of Verona Pharma (VRNA) in Q2 2021, closing a stake of 18,337 shares — an estimated $153K sold.

DAFNA Capital Management first reported a position in VRNA in Q3 2020 and held it in 3 quarters. The position peaked at $1.13M in Q4 2020. 37 funds tracked by Wall St. Rank hold VRNA as of Q2 2021.

  • DAFNA Capital Management reported no remaining Verona Pharma position as of Q2 2021 after selling out during the quarter.
  • DAFNA Capital Management sold 18,337 Verona Pharma shares in Q2 2021, an estimated $153K.
  • DAFNA Capital Management first reported a position in Verona Pharma in Q3 2020 and held it in 3 quarters.
  • DAFNA Capital Management's Verona Pharma position peaked at $1.13M in Q4 2020.
  • 37 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2021.

Based on DAFNA Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.